About US
Contact us
-
Orca Bio, hunting cell therapy's production white whale, tees up new commercial plantWith manufacturing a major hang-up for cell therapies, late-stage player Orca Bio is also looking beyond the clinic. Orca, focused on development of precision cell therapies for cancer, g2022/9/9
-
Targeting $500M opportunity, Amneal files for FDA approval of extended-release Parkinson's prospectAmneal Pharmaceuticals hasfiledfor FDA approval of an extended-release Parkinson’s disease prospect that is tipped to deliver peak U.S. sales of up to $500 million. With Amneal hitting its third-quar2022/9/6
-
Fierce Pharma Asia—Biocon's biosimilar production faults; Fosun unit's PD-1 plan; Takeda-Finch IBD severanceBiocon'sbiosimilar manufacturing sites were hitwith several FDA Forms 483. Fosun Pharma's Shanghai Henlius Biotech is looking for a U.S. partner for its PD-1 inhibitor as the company shifts focus fro2022/9/6
-
AstraZeneca scores injunction to temporarily halt former exec's start at crosstown rival GSKAstraZeneca has logged a last-minute victory—for now—in its executive tug of war with GSK. Just hours before outgoing AZ exec Chris Sheldon was set to take up his post at crosstown rival2022/9/1
-
Bayer’s BlueRock inks cardiovascular cell therapy delivery dealBayer’s BlueRock Therapeutics haspartneredwith BioCardia on the delivery of cell therapies, paying a “sizable” upfront fee to access minimally invasive technology that could get its heart failure can2022/9/1
-
Amid launch efforts, Neurocrine doles out £48M to acquire small UK biotech DiurnalAs Neurocrine Biosciences grows through U.S.drug launches, the company is simultaneouslyaiming to expand its global reach with a small buyout. Neurocrine Biosciences shelled out £48.3 (ap2022/8/30
-
Amgen's Lumakras triumphs in confirmatory trial, threatening Mirati's accelerated approval windowAmgen has bagged the first randomized clinical trial win in the KRAS inhibitor class of cancer medicines. But for potential runner-up Mirati Therapeutics, it could bode ill beyond just a temporary da2022/8/30
-
Bavarian Nordic ramps up monkeypox vaccine manufacturing capacity, reopens bulk facilityBavarian Nordic has been scrambling to ramp up supply of the only approved monkeypox vaccine, Jynneos, to meet growing global demand. The Danish company’s latest efforts include exploring reusing tec2022/8/26
-
Johnson & Johnson lost to Pfizer in bidding war for Global Blood Therapeutics: BloombergBefore settling on a $5.4 billion price tag for Global Blood Therapeutics, Pfizer had to fight off a mysterious “company A.” Now, the identity of that contender has been revealed. Johnson2022/8/26
-
Pfizer partner CStone explores sale as US path blocked, Chinese competition heats up: BloombergA Pfizer cancer drug partner in China is considering a sale as the biotech’s commercial path in the U.S. looks uncertain and competition in its home country intensifies. CStone Pharmaceut2022/8/24